fenofibrate has been researched along with Hyperlipoproteinemia in 31 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "According clinical tests which included almost 200 patients with mixed hyperlipoproteinemia, Fenofibrate 250 SR Pharmavit stands for an effective and well tolerated hypolipidemics." | 9.09 | [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic]. ( Ceska, R; Stulc, T, 2000) |
| "Fenofibrate, a phenoxyacid derivative, given at daily dose of 300mg during 1 year following a single blind design, lowered significantly serum triglycerides and total cholesterol in patients various types of hyperlipoproteinemias (IIa, IV, V), fibrate significantly reduced plasma uric acid." | 9.05 | Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. ( Desager, JP; Harvengt, C; Heller, F, 1980) |
| " Afterwards, they were treated with fenofibrate (Katalip) in a dosage of 100 mg, 2 capsules in the morning and 1 in the evening." | 5.28 | [The effect of fenofibrate in various types of hyperlipoproteinemias]. ( Sucić, M, 1989) |
| "Fenofibrate is a potent hypolipemic agent, widely used in patients with mild to severe renal failure in whom hyperlipoproteinemia is frequent." | 5.09 | [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. ( Achard, JM; el Esper, N; Fournier, A; Hottelart, C; Pruna, A, 1999) |
| "According clinical tests which included almost 200 patients with mixed hyperlipoproteinemia, Fenofibrate 250 SR Pharmavit stands for an effective and well tolerated hypolipidemics." | 5.09 | [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic]. ( Ceska, R; Stulc, T, 2000) |
| "Fenofibrate, a phenoxyacid derivative, given at daily dose of 300mg during 1 year following a single blind design, lowered significantly serum triglycerides and total cholesterol in patients various types of hyperlipoproteinemias (IIa, IV, V), fibrate significantly reduced plasma uric acid." | 5.05 | Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. ( Desager, JP; Harvengt, C; Heller, F, 1980) |
| "Fenofibrate effect on plasma lipids and lipoproteins was studied in 23 patients with primary hyperlipoproteinemias (HLP): 12 with familial hypercholesterolemia (FH), 5 with combined HLP and 6 with Type III HLP." | 3.67 | Long term-effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias. ( Baggio, G; Ciuffetti, G; Crepaldi, G; Fellin, R; Gabelli, C; Gasparotto, A; Senin, U; Valerio, G, 1986) |
| "The effect of fenofibrate treatment on serum cholesterol levels was studied in relation to the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in mononuclear cells from patients with hyperlipoproteinemia type IIa and IIb." | 3.67 | Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. ( Ditschuneit, H; Ditschuneit, HH; Schneider, A; Stange, EF, 1985) |
| "In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels." | 2.73 | Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. ( Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M, 2007) |
| "Fenofibrate (300 mg/day) was then given for 2 periods of 2 months, each separated by a 2-month period in which only the dietary treatment was continued." | 1.27 | Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states. ( Avogaro, P; Belussi, F; Bittolo Bon, G; Cazzolato, G; Pontoglio, E, 1983) |
| "Fenofibrate was well tolerated." | 1.26 | [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]. ( Gustafson, A; Micheli, H; Pometta, D, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (67.74) | 18.7374 |
| 1990's | 5 (16.13) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brouillette, C | 1 |
| Bossé, Y | 1 |
| Pérusse, L | 1 |
| Gaudet, D | 1 |
| Vohl, MC | 1 |
| Otto, C | 1 |
| Otto, B | 1 |
| Frost, RJ | 1 |
| Vogeser, M | 1 |
| Pfeiffer, AF | 1 |
| Spranger, J | 1 |
| Parhofer, KG | 1 |
| Häring, HU | 1 |
| Schleicher, E | 1 |
| Renner, R | 1 |
| Mehnert, H | 1 |
| von Bergmann, K | 1 |
| Leiss, O | 1 |
| Gariot, P | 1 |
| Pointel, JP | 1 |
| Barrat, E | 1 |
| Drouin, P | 1 |
| Debry, G | 1 |
| Viikari, J | 1 |
| Solakivi-Jaakkola, T | 1 |
| Lehtonen, A | 1 |
| Kalinová, M | 1 |
| Zadák, Z | 1 |
| Sobotka, L | 1 |
| Avogaro, P | 1 |
| Bittolo Bon, G | 1 |
| Belussi, F | 1 |
| Pontoglio, E | 1 |
| Cazzolato, G | 1 |
| Rouffy, J | 1 |
| Sauvanet, JP | 1 |
| Chanu, B | 1 |
| Bakir, R | 1 |
| Goy-Loeper, J | 1 |
| Saya, C | 1 |
| Pinaroli, F | 1 |
| Micheli, H | 2 |
| Pometta, D | 2 |
| Gustafson, A | 1 |
| Harvengt, C | 1 |
| Heller, F | 1 |
| Desager, JP | 1 |
| Schwartzkopff, W | 1 |
| Schilling, A | 1 |
| Wilczek, H | 1 |
| Sobra, J | 2 |
| Ceska, R | 3 |
| Justová, V | 1 |
| Procházková, R | 2 |
| Kvasilová, M | 2 |
| Jůzová, Z | 1 |
| Hottelart, C | 1 |
| el Esper, N | 1 |
| Achard, JM | 1 |
| Pruna, A | 1 |
| Fournier, A | 1 |
| Stulc, T | 1 |
| Soska, V | 1 |
| Mayer, O | 1 |
| Milionis, HJ | 1 |
| Bairaktari, ET | 1 |
| Liberopoulos, EN | 1 |
| Elisaf, MS | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Szostak, WB | 1 |
| Hajós, P | 1 |
| Tornyossi, M | 1 |
| Knopp, RH | 1 |
| Sucić, M | 1 |
| Brown, WV | 2 |
| Reiner, Z | 1 |
| Salzer, B | 1 |
| Kes, P | 1 |
| Smud, R | 1 |
| Sermukslis, B | 1 |
| Baggio, G | 1 |
| Gasparotto, A | 1 |
| Ciuffetti, G | 1 |
| Valerio, G | 1 |
| Fellin, R | 1 |
| Senin, U | 1 |
| Gabelli, C | 1 |
| Crepaldi, G | 1 |
| Tesone, PA | 1 |
| Gladstein, J | 1 |
| Acuña, AM | 1 |
| Schneider, A | 1 |
| Stange, EF | 1 |
| Ditschuneit, HH | 1 |
| Ditschuneit, H | 1 |
3 reviews available for fenofibrate and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Present status of fibrates in the treatment of hyperlipoproteinemias].
Topics: Bezafibrate; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents | 1999 |
Review of the effects of fenofibrate on lipoproteins, apoproteins, and bile saturation: US studies.
Topics: Adult; Aged; Apoproteins; Bile Acids and Salts; Cholesterol; Clinical Trials as Topic; Double-Blind | 1989 |
Focus on fenofibrate.
Topics: Anticholesteremic Agents; Cholesterol; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 1988 |
9 trials available for fenofibrate and Hyperlipoproteinemia
| Article | Year |
|---|---|
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus | 2007 |
Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
Topics: Bezafibrate; Bile; Cholesterol; Female; Fenofibrate; Gallbladder; Humans; Hyperlipoproteinemias; Hyp | 1984 |
Effect of procetofen on apolipoprotein A I and B concentrations in hyperlipoproteinemia.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Choles | 1982 |
Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.
Topics: Adult; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Middle Aged; Propio | 1980 |
[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
Topics: Aged; Creatinine; Cross-Over Studies; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Hyper | 1999 |
[Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].
Topics: Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged | 2000 |
Review of the effects of fenofibrate on lipoproteins, apoproteins, and bile saturation: US studies.
Topics: Adult; Aged; Apoproteins; Bile Acids and Salts; Cholesterol; Clinical Trials as Topic; Double-Blind | 1989 |
Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double- | 1987 |
Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials | 1985 |
20 other studies available for fenofibrate and Hyperlipoproteinemia
| Article | Year |
|---|---|
Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.
Topics: Adult; Aged; Body Mass Index; Carrier Proteins; Chromosome Mapping; Fatty Acid-Binding Proteins; Fem | 2004 |
[The effect of fenofibrate on the lipid level in diabetic patients].
Topics: Aged; Diabetes Complications; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agen | 1983 |
[Morphometric study of hepatic peroxisomes in hyperlipoproteinemic patients treated with fenofibrate].
Topics: Adult; Aged; Animals; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Live | 1984 |
[Treatment of hyperlipoproteinemia with lipanthyl].
Topics: Female; Fenofibrate; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Male; Middle Aged; Propion | 1983 |
Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Diet; Female; Fenofibrate; Humans; Hypercholesterolemia; | 1983 |
[Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
Topics: Adolescent; Adult; Aged; Apolipoproteins; Apolipoproteins B; Cholesterol; Female; Fenofibrate; Human | 1980 |
[Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
Topics: Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Cholesterol; Female; Fenofibrate; Humans; Hyp | 1980 |
[Procetofen in the treatment of hyperlipoproteinaemias (author's transl)].
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Male; Middle Aged; Pro | 1980 |
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
Topics: Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Fenofibrate; Hum | 1980 |
[Therapy with fibrates and vitamin D metabolism].
Topics: Adult; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; M | 1993 |
[On the article by Dr. R. Ceska, et al: Fenofibrat Pharmavit SR 250 in patients with mixed hyperlipoproteinemia].
Topics: Dosage Forms; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents | 2001 |
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Hum | 2001 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; | 1991 |
[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
Topics: Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle A | 1990 |
Effect of lipanthyl in hyperlipoproteinaemic diabetic patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fe | 1989 |
[The effect of fenofibrate in various types of hyperlipoproteinemias].
Topics: Adult; Fenofibrate; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Middle Aged; Propionates | 1989 |
[Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV | 1988 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
Long term-effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias.
Topics: Cholesterol; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipop | 1986 |
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Fenofibrate; Humans; Hydroxymethylglutaryl CoA R | 1985 |